Capricor Therapeutics Investors with Significant Losses Have a Legal Path Forward
In a pivotal development for investors, the Rosen Law Firm has issued a reminder regarding a significant opportunity for purchasers of Capricor Therapeutics, Inc. (NASDAQ: CAPR). Those who bought securities between December 17, 2025, and July 26, 2026, may be entitled to join a class action lawsuit addressing allegations of securities fraud. The deadline to act as the lead plaintiff is September 28, 2026, allowing affected investors to take steps towards securing potential compensation for their losses.
The class action arises from concerns that Capricor made false statements concerning its product, Deramiocel, which is aimed at treating Duchenne muscular dystrophy. Specifically, the allegations suggest that Capricor did not disclose critical information related to a change in the statistical analysis plan used for the product's clinical data evaluation, which had not been approved by the FDA before the resubmission of its Biologics License Application (BLA). Consequently, concerns about the regulatory approval for Deramiocel's efficacy arose.
Investors impacted by this announcement are urged to take action. To join the lawsuit or to learn more, interested parties can visit the Rosen Law Firm’s website or contact attorney Phillip Kim directly. The Rosen Law Firm stands out due to its commendable success track and has achieved remarkable settlements for securities class actions in the past.
Additionally, this class action lawsuit allows investors to avoid any upfront payment for legal fees, as the firm operates on a contingency fee basis. This means that any compensation secured through the lawsuit will only be charged if a successful outcome is attained.
Investors should note that, as of now, the class has not yet been certified. This means that you remain unrepresented unless you take further action to secure legal counsel. Acting quickly is essential, especially for those wishing to represent other class members as a lead plaintiff in this lawsuit.
The Rosen Law Firm emphasizes the importance of choosing a qualified legal representative. Unlike some firms that do not possess the necessary experience in handling complex securities matters, Rosen Law boasts a recognized track record of not only advocating for investor rights but also winning significant settlements. With a substantial sum of over $438 million recovered for investors in a previous year alone, the firm positions itself as a leader in this type of legal work.
Potential plaintiffs are encouraged to review all of their available options thoroughly and decide accordingly. Those who wish to explore the possibility of leading the action can do so by contacting Rosen Law Firm and expressing their interest before the imminent deadline. With proper legal support, affected investors can navigate the complexities of this lawsuit more effectively. Follow the Rosen Law Firm on their professional social media platforms for ongoing updates and guidance on this case, particularly as the deadline approaches.
In conclusion, if you purchased securities from Capricor Therapeutics during the specified period and believe you may be eligible for compensation, do not delay in reaching out to the Rosen Law Firm. Your rights as an investor are crucial and pursuing legal action can help rectify the financial damages you might have encountered due to the alleged misleading information that significantly affected stock value.
The class action arises from concerns that Capricor made false statements concerning its product, Deramiocel, which is aimed at treating Duchenne muscular dystrophy. Specifically, the allegations suggest that Capricor did not disclose critical information related to a change in the statistical analysis plan used for the product's clinical data evaluation, which had not been approved by the FDA before the resubmission of its Biologics License Application (BLA). Consequently, concerns about the regulatory approval for Deramiocel's efficacy arose.
Investors impacted by this announcement are urged to take action. To join the lawsuit or to learn more, interested parties can visit the Rosen Law Firm’s website or contact attorney Phillip Kim directly. The Rosen Law Firm stands out due to its commendable success track and has achieved remarkable settlements for securities class actions in the past.
Additionally, this class action lawsuit allows investors to avoid any upfront payment for legal fees, as the firm operates on a contingency fee basis. This means that any compensation secured through the lawsuit will only be charged if a successful outcome is attained.
Investors should note that, as of now, the class has not yet been certified. This means that you remain unrepresented unless you take further action to secure legal counsel. Acting quickly is essential, especially for those wishing to represent other class members as a lead plaintiff in this lawsuit.
The Rosen Law Firm emphasizes the importance of choosing a qualified legal representative. Unlike some firms that do not possess the necessary experience in handling complex securities matters, Rosen Law boasts a recognized track record of not only advocating for investor rights but also winning significant settlements. With a substantial sum of over $438 million recovered for investors in a previous year alone, the firm positions itself as a leader in this type of legal work.
Potential plaintiffs are encouraged to review all of their available options thoroughly and decide accordingly. Those who wish to explore the possibility of leading the action can do so by contacting Rosen Law Firm and expressing their interest before the imminent deadline. With proper legal support, affected investors can navigate the complexities of this lawsuit more effectively. Follow the Rosen Law Firm on their professional social media platforms for ongoing updates and guidance on this case, particularly as the deadline approaches.
In conclusion, if you purchased securities from Capricor Therapeutics during the specified period and believe you may be eligible for compensation, do not delay in reaching out to the Rosen Law Firm. Your rights as an investor are crucial and pursuing legal action can help rectify the financial damages you might have encountered due to the alleged misleading information that significantly affected stock value.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.